{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T08:25:06Z","timestamp":1791707106312,"version":"4.3.4"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["U01CA199334"],"award-info":[{"award-number":["U01CA199334"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ajog.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Obstetrics and Gynecology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.ajog.2021.09.012","type":"journal-article","created":{"date-parts":[[2021,9,20]],"date-time":"2021-09-20T02:03:08Z","timestamp":1632103388000},"page":"228.e1-228.e9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Cost-effectiveness analysis of the 2019 American Society for Colposcopy and Cervical Pathology Risk-Based Management Consensus Guidelines for the management of abnormal cervical cancer screening tests and cancer precursors"],"prefix":"10.1016","volume":"226","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0290-5148","authenticated-orcid":false,"given":"Vidit N.","family":"Munshi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca B.","family":"Perkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Sy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane J.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ajog.2021.09.012_bib1","doi-asserted-by":"crossref","DOI":"10.7326\/0003-4819-156-12-201206190-00424","article-title":"Screening for cervical cancer: US Preventive Services Task Force recommendation statement","volume":"156","author":"Moyer","year":"2012","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ajog.2021.09.012_bib2","first-page":"37","article-title":"ACOG practice bulletin. Cervical Cytology screening. Number 45, August 2003","volume":"83","year":"2003","journal-title":"Int J Gynecol Obstet"},{"key":"10.1016\/j.ajog.2021.09.012_bib3","doi-asserted-by":"crossref","DOI":"10.1016\/j.pop.2008.10.008","article-title":"Cervical cancer screening and updated Pap guidelines","volume":"36","author":"Warren","year":"2009","journal-title":"Prim Care"},{"key":"10.1016\/j.ajog.2021.09.012_bib4","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1001\/jama.2018.10897","article-title":"Screening for cervical cancer: US Preventive Services Task Force recommendation statement","volume":"320","author":"Curry","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.ajog.2021.09.012_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/lgt.0b013e31815ea58b","article-title":"Risk assessment to guide the prevention of cervical cancer","volume":"12","author":"Castle","year":"2008","journal-title":"J\u00a0Low Genit Tract Dis"},{"key":"10.1016\/j.ajog.2021.09.012_bib6","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nrclinonc.2016.101","article-title":"Screening: a risk-based framework to decide who benefits from screening","volume":"13","author":"Castle","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ajog.2021.09.012_bib7","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1097\/LGT.0b013e318287d329","article-title":"2012 updated consensus guidelines for the management of abnormal cervical cancer screening tests and cancer precursors","volume":"17","author":"Massad","year":"2013","journal-title":"J\u00a0Low Genit Tract Dis"},{"key":"10.1016\/j.ajog.2021.09.012_bib8","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ajog.2007.07.047","article-title":"2006 consensus guidelines for the management of women with abnormal cervical cancer screening tests","volume":"197","author":"Wright","year":"2007","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.09.012_bib9","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1097\/LGT.0000000000000525","article-title":"2019 ASCCP risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors","volume":"24","author":"Perkins","year":"2020","journal-title":"J\u00a0Low Genit Tract Dis"},{"key":"10.1016\/j.ajog.2021.09.012_bib10","doi-asserted-by":"crossref","first-page":"20","DOI":"10.7326\/M17-1609","article-title":"Effect of several negative rounds of human papillomavirus and cytology co-testing on safety against cervical cancer: an observational cohort study","volume":"168","author":"Castle","year":"2018","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ajog.2021.09.012_bib11","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/S1470-2045(11)70145-0","article-title":"Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice","volume":"12","author":"Katki","year":"2011","journal-title":"Lancet Oncol"},{"issue":"Suppl 1","key":"10.1016\/j.ajog.2021.09.012_bib12","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1097\/LGT.0b013e318285437b","article-title":"Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive","volume":"17","author":"Katki","year":"2013","journal-title":"J\u00a0Low Genit Tract Dis"},{"key":"10.1016\/j.ajog.2021.09.012_bib13","doi-asserted-by":"crossref","first-page":"59S","DOI":"10.1097\/01.AOG.0000514819.18583.11","article-title":"Compliance with ASCCP guidelines for evaluation and management of abnormal pap smears [28E]","volume":"129","author":"Hedman","year":"2017","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.ajog.2021.09.012_bib14","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1097\/LGT.0000000000000528","article-title":"2019 ASCCP risk-based management consensus guidelines: methods for risk estimation, recommended management, and validation","volume":"24","author":"Cheung","year":"2020","journal-title":"J\u00a0Low Genit Tract Dis"},{"key":"10.1016\/j.ajog.2021.09.012_bib15","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1097\/LGT.0000000000000529","article-title":"Risk estimates supporting the 2019 ASCCP Risk-Based Management Consensus Guidelines","volume":"24","author":"Egemen","year":"2020","journal-title":"J\u00a0Low Genit Tract Dis"},{"key":"10.1016\/j.ajog.2021.09.012_bib16","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw216","article-title":"Optimal cervical cancer screening in women vaccinated against human papillomavirus","volume":"109","author":"Kim","year":"2017","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ajog.2021.09.012_bib17","doi-asserted-by":"crossref","first-page":"589","DOI":"10.7326\/M15-0420","article-title":"Inefficiencies and high-value improvements in US Cervical cancer screening practice: a cost-effectiveness analysis","volume":"163","author":"Kim","year":"2015","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ajog.2021.09.012_bib18","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1093\/aje\/kwu159","article-title":"An updated natural history model of cervical cancer: derivation of model parameters","volume":"180","author":"Campos","year":"2014","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ajog.2021.09.012_bib19","doi-asserted-by":"crossref","first-page":"538","DOI":"10.7326\/0003-4819-151-8-200910200-00007","article-title":"Cost-effectiveness of human papillomavirus vaccination and cervical cancer screening in women older than 30 years in the United States","volume":"151","author":"Kim","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.ajog.2021.09.012_bib20","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/aje\/kwm086","article-title":"Multiparameter calibration of a natural history model of cervical cancer","volume":"166","author":"Kim","year":"2007","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.ajog.2021.09.012_bib21","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.ypmed.2017.12.023","article-title":"Adherence patterns to extended cervical screening intervals in women undergoing human papillomavirus (HPV) and cytology cotesting","volume":"109","author":"Rendle","year":"2018","journal-title":"Prev Med"},{"key":"10.1016\/j.ajog.2021.09.012_bib22","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1016\/j.ygyno.2013.12.037","article-title":"Cervical excisional treatment of young women: a population-based study","volume":"132","author":"Kinney","year":"2014","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ajog.2021.09.012_bib23","doi-asserted-by":"crossref","first-page":"2854","DOI":"10.1002\/ijc.29337","article-title":"Human papillomavirus testing 2007\u20132012: co-testing and triage utilization and impact on subsequent clinical management","volume":"136","author":"Cuzick","year":"2015","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ajog.2021.09.012_bib24","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1056\/NEJMp1405158","article-title":"Updating cost-effectiveness\u2014the curious resilience of the $50,000-per-QALY threshold","volume":"371","author":"Neumann","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ajog.2021.09.012_bib25","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1001\/jama.2016.12195","article-title":"Recommendations for conduct, methodological practices, and reporting of cost-effectiveness analyses: second panel on cost-effectiveness in health and medicine","volume":"316","author":"Sanders","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.ajog.2021.09.012_bib26","first-page":"321","article-title":"Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society","volume":"70","author":"Fontham","year":"2020","journal-title":"CA Cancer J Clin"}],"container-title":["American Journal of Obstetrics and Gynecology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937821010097?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002937821010097?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T11:34:28Z","timestamp":1757590468000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002937821010097"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S0002937821010097"],"URL":"https:\/\/doi.org\/10.1016\/j.ajog.2021.09.012","relation":{},"ISSN":["0002-9378"],"issn-type":[{"value":"0002-9378","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cost-effectiveness analysis of the 2019 American Society for Colposcopy and Cervical Pathology Risk-Based Management Consensus Guidelines for the management of abnormal cervical cancer screening tests and cancer precursors","name":"articletitle","label":"Article Title"},{"value":"American Journal of Obstetrics and Gynecology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ajog.2021.09.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}